Tags : MicroTransponder

PharmaShots Weekly Snapshots (August 30 – September 03, 2021)

Tuba Khan September 3, 2021

Forte’s FB-401 Fails to Meet Primary Endpoints in P-II Clinical Trial For the Treatment of Atopic Dermatitis Published: Sept 3, 2021 | Tags: Forte, FB-401, P-II, Clinical Trial, Atopic Dermatitis […]readmore

MedTech

MicroTransponder Receives the US FDA’s Approval for Vivistim System as

Tuba Khan August 30, 2021

Shots: The approval is based on a study of 108 patients in the US and the UK, that showed patients treated with the Vivistim system had improved mobility than patients […]readmore

Tags : MicroTransponder

PharmaShots Weekly Snapshots (August 30 – September 03, 2021)

MicroTransponder Receives the US FDA’s Approval for Vivistim System as

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : MicroTransponder

PharmaShots Weekly Snapshots (August 30 – September 03, 2021)

MicroTransponder Receives the US FDA’s Approval for Vivistim System as

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company